The study of AVL-292-001 was a double-blind, placebo-controlled, single ascending dose study in healthy volunteers and in this study AVL-292 demonstrated favorable safety, tolerability and pharmacokinetics.
In addition, the trial used Avila’s unique covalent probe technology to assess the quantitative relationship among dose level, systemic exposure, and occupancy of the target by AVL- 292.
This combination of analyses provides an understanding of AVL-292 action at the molecular level and serves as a rational guide to future clinical development.
Avila CEO Katrine Bosley said over 50 healthy volunteers participated in these two trials, based on these results, they are actively advancing the clinical development of AVL-292, initially for the treatment of B cell cancers, with a Phase 1b study expected to initiate in mid-2011.
AVL-292 is an orally available, covalent drug which selectively and covalently binds to Btk to inactivate and silence its activity.